DATROWAY approved in China for patients with previously treated metastatic HR Positive, HER2 negative breast...

ENHERTU approved in Japan as first HER2 directed medicine for patients with HER2 low or...

Genmab receives FDA Breakthrough Therapy Designation for Rinatabart sesutecan (Rina-S) in advanced endometrial cancer (EC)

HERTHENA-Breast04 Phase 3 trial of Patritumab deruxtecan initiated in patients with metastatic hormone receptor positive,...

Koas acquires antibody drug developer Novelty Nobility

Indena and TCG GreenChem join forces to advance next-generation ADC technologies